Kymera Therapeutics (KYMR) has shared an update.
Kymera Therapeutics, Inc. has announced an exciting development: their partner Sanofi plans to expand Phase 2 trials for their drug KT-474, targeting Hidradenitis Suppurativa and Atopic Dermatitis. This move is aimed at accelerating the path to pivotal studies after positive preliminary safety and efficacy data were reviewed by an independent committee. This could be significant news for investors tracking advancements in the biotech sector.
See more insights into KYMR stock on TipRanks’ Stock Analysis page.
